Breast Cancer Gene Puts Survivors at Higher Odds for Recurrence
THURSDAY, Dec. 8 (HealthDay News) -- Breast cancer survivors
carrying specific genetic mutations, known as BRCA1 or BRCA2, have
a 10 percent greater risk for developing cancer in their other
breast, and the risk rises further when a woman receives her first
diagnosis before age 40, new research suggests.
Few With Acute Kidney Injury See Specialists, Study Finds
THURSDAY, Dec. 8 (HealthDay News) -- Many Americans who
experience acute kidney injury that does not get better do not see
a kidney specialist within a year, which suggests that doctors need
to do more to identify and treat these patients, a new study
reveals.
Avastin Boosted Survival for Type of Aggressive Breast Cancer: Study
WEDNESDAY, Dec. 7 (HealthDay News) -- In November, the U.S. Food
and Drug Administration revoked its approval of the drug Avastin
for the treatment of breast cancer. But, a new study suggests that
the drug can boost the survival of women with a specific type of
aggressive breast tumor when used in conjunction with two other
medications.
Family Tree May Affect Diagnosis Age in Some Breast Cancers
THURSDAY, Dec. 8 (HealthDay News) -- Some women who inherit the
BRCA1 or BRCA2 breast and ovarian cancer genes from their father
may be diagnosed with breast cancer nearly a decade earlier than
those who inherit the genes from their mother, a new study
indicates.
Two New Drug Combos May Fight Advanced Breast Cancers
WEDNESDAY, Dec. 7 (HealthDay News) -- Breast cancer researchers
report they are heartened by the results of two new studies that
show combination therapies might improve survival for women with
two different types of advanced tumors.
More Americans Exercise, but Arthritis Can Get in the Way
THURSDAY, Dec. 8 (HealthDay News) -- Exercise is good medicine,
and the number of American adults who did no physical activity in
their leisure time decreased from 31 percent in 1989 to 25 percent
in 2008, researchers have found.
CDC Issues New TB Treatment Guidelines
THURSDAY, Dec. 8 (HealthDay News) -- New guidelines on treating
so-called "latent" tuberculosis infection in the United States
should significantly shorten and simplify the course of the therapy
from about 9 months to 3 months, according to the U.S. Centers for
Disease Control and Prevention.